Treatment of Uveal Melanoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2015-11-25

AUTHORS

Alexander N. Shoushtari , Richard D. Carvajal

ABSTRACT

Uveal melanoma (UM) comprises approximately 5 % of all melanoma diagnoses in the USA each year. Approximately half of patients with UM eventually develop metastases, most commonly involving the liver. Historically, prognosis for these patients has been poor, with death occurring 6–12 months from the time of metastases. Multiple trials of cytotoxic treatments largely extrapolated from cutaneous melanoma have been ineffective in metastatic UM. Trials of regional hepatic-directed therapy have led to high response rates, but these have yet to be translated into a survival benefit. Recently, it was discovered that the majority of UMs harbor activating mutations in genes encoding one of two G-alpha protein subunits, GNAQ and GNA11. This knowledge has led to the rational development of clinical trials specifically for UM utilizing targeted inhibitors of the activated signaling pathways such as mitogen-activated protein kinase, Akt, and protein kinase C. A recent trial of the oral MEK inhibitor selumetinib was the first to show clinical benefit for any systemic therapy in a randomized fashion. This increasing understanding of the biology of UM offers hope that novel treatments will continue to benefit patients with metastatic disease. More... »

PAGES

281-293

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-22539-5_12

DOI

http://dx.doi.org/10.1007/978-3-319-22539-5_12

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017912042

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26601868


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uveal Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shoushtari", 
        "givenName": "Alexander N.", 
        "id": "sg:person.01121172646.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121172646.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Melanoma and Experimental Therapeutics Services, Columbia University Medical Center, 161 Fort Washington Avenue, 10032, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239585.0", 
          "name": [
            "Melanoma and Experimental Therapeutics Services, Columbia University Medical Center, 161 Fort Washington Avenue, 10032, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2015-11-25", 
    "datePublishedReg": "2015-11-25", 
    "description": "Uveal melanoma (UM) comprises approximately 5\u00a0% of all melanoma diagnoses in the USA each year. Approximately half of patients with UM eventually develop metastases, most commonly involving the liver. Historically, prognosis for these patients has been poor, with death occurring 6\u201312\u00a0months from the time of metastases. Multiple trials of cytotoxic treatments largely extrapolated from cutaneous melanoma have been ineffective in metastatic UM. Trials of regional hepatic-directed therapy have led to high response rates, but these have yet to be translated into a survival benefit. Recently, it was discovered that the majority of UMs harbor activating mutations in genes encoding one of two G-alpha protein subunits, GNAQ and GNA11. This knowledge has led to the rational development of clinical trials specifically for UM utilizing targeted inhibitors of the activated signaling pathways such as mitogen-activated protein kinase, Akt, and protein kinase C. A recent trial of the oral MEK inhibitor selumetinib was the first to show clinical benefit for any systemic therapy in a randomized fashion. This increasing understanding of the biology of UM offers hope that novel treatments will continue to benefit patients with metastatic disease.", 
    "editor": [
      {
        "familyName": "Kaufman", 
        "givenName": "Howard L.", 
        "type": "Person"
      }, 
      {
        "familyName": "Mehnert", 
        "givenName": "Janice M.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-22539-5_12", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-22538-8", 
        "978-3-319-22539-5"
      ], 
      "name": "Melanoma", 
      "type": "Book"
    }, 
    "keywords": [
      "uveal melanoma", 
      "biology of UM", 
      "time of metastasis", 
      "hepatic-directed therapy", 
      "half of patients", 
      "metastatic uveal melanoma", 
      "MEK inhibitor selumetinib", 
      "high response rate", 
      "survival benefit", 
      "systemic therapy", 
      "metastatic disease", 
      "clinical benefit", 
      "cutaneous melanoma", 
      "recent trials", 
      "cytotoxic treatment", 
      "clinical trials", 
      "randomized fashion", 
      "novel treatments", 
      "response rate", 
      "activating mutations", 
      "mitogen-activated protein kinase", 
      "patients", 
      "melanoma", 
      "trials", 
      "melanoma diagnosis", 
      "metastasis", 
      "therapy", 
      "multiple trials", 
      "treatment", 
      "protein kinase C.", 
      "kinase C.", 
      "G alpha protein subunits", 
      "prognosis", 
      "protein kinase", 
      "selumetinib", 
      "rational development", 
      "disease", 
      "diagnosis", 
      "liver", 
      "GNA11", 
      "months", 
      "GNAQ", 
      "death", 
      "Akt", 
      "inhibitors", 
      "benefits", 
      "majority", 
      "years", 
      "pathway", 
      "mutations", 
      "kinase", 
      "half", 
      "protein subunits", 
      "genes", 
      "C.", 
      "rate", 
      "subunits", 
      "fashion", 
      "hope", 
      "development", 
      "biology", 
      "knowledge", 
      "time", 
      "understanding", 
      "USA"
    ], 
    "name": "Treatment of Uveal Melanoma", 
    "pagination": "281-293", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017912042"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-22539-5_12"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26601868"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-22539-5_12", 
      "https://app.dimensions.ai/details/publication/pub.1017912042"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_23.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-22539-5_12"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-22539-5_12'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-22539-5_12'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-22539-5_12'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-22539-5_12'


 

This table displays all metadata directly associated to this object as RDF triples.

175 TRIPLES      22 PREDICATES      98 URIs      91 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-22539-5_12 schema:about N23402d1de43145b08f147e818c4bb08d
2 N3edeb008b3724f63955ca1dcc32c7e2a
3 N51374dfae47143259674d31d0d165a90
4 N58cf14a13d1f426798a2b1a593c4b888
5 N8fded5880d2048aca1afe621e6f52def
6 N9afe88cf538b4cf8b1f5fcd76c16279d
7 Nf3ae2515de8142c98f0bcc4fe413b7a7
8 Nf42e6dcdb29942c2880ee2c7870206d5
9 anzsrc-for:11
10 anzsrc-for:1112
11 schema:author Nbdfd3ef30aa740c0a6cf9a580df50f27
12 schema:datePublished 2015-11-25
13 schema:datePublishedReg 2015-11-25
14 schema:description Uveal melanoma (UM) comprises approximately 5 % of all melanoma diagnoses in the USA each year. Approximately half of patients with UM eventually develop metastases, most commonly involving the liver. Historically, prognosis for these patients has been poor, with death occurring 6–12 months from the time of metastases. Multiple trials of cytotoxic treatments largely extrapolated from cutaneous melanoma have been ineffective in metastatic UM. Trials of regional hepatic-directed therapy have led to high response rates, but these have yet to be translated into a survival benefit. Recently, it was discovered that the majority of UMs harbor activating mutations in genes encoding one of two G-alpha protein subunits, GNAQ and GNA11. This knowledge has led to the rational development of clinical trials specifically for UM utilizing targeted inhibitors of the activated signaling pathways such as mitogen-activated protein kinase, Akt, and protein kinase C. A recent trial of the oral MEK inhibitor selumetinib was the first to show clinical benefit for any systemic therapy in a randomized fashion. This increasing understanding of the biology of UM offers hope that novel treatments will continue to benefit patients with metastatic disease.
15 schema:editor N04e1af42f25c4970b5e0f475adebdd53
16 schema:genre chapter
17 schema:isAccessibleForFree false
18 schema:isPartOf N0e00557dead545168e72654602757f15
19 schema:keywords Akt
20 C.
21 G alpha protein subunits
22 GNA11
23 GNAQ
24 MEK inhibitor selumetinib
25 USA
26 activating mutations
27 benefits
28 biology
29 biology of UM
30 clinical benefit
31 clinical trials
32 cutaneous melanoma
33 cytotoxic treatment
34 death
35 development
36 diagnosis
37 disease
38 fashion
39 genes
40 half
41 half of patients
42 hepatic-directed therapy
43 high response rate
44 hope
45 inhibitors
46 kinase
47 kinase C.
48 knowledge
49 liver
50 majority
51 melanoma
52 melanoma diagnosis
53 metastasis
54 metastatic disease
55 metastatic uveal melanoma
56 mitogen-activated protein kinase
57 months
58 multiple trials
59 mutations
60 novel treatments
61 pathway
62 patients
63 prognosis
64 protein kinase
65 protein kinase C.
66 protein subunits
67 randomized fashion
68 rate
69 rational development
70 recent trials
71 response rate
72 selumetinib
73 subunits
74 survival benefit
75 systemic therapy
76 therapy
77 time
78 time of metastasis
79 treatment
80 trials
81 understanding
82 uveal melanoma
83 years
84 schema:name Treatment of Uveal Melanoma
85 schema:pagination 281-293
86 schema:productId N018c392b2448417ca7a959e8c9f6cc1e
87 N8bb6d07e409642aab7e48739077e36f1
88 Nf1cd30279932483aa8987ad19b5bd747
89 schema:publisher Nd1bf24005c344baab87e348565143bb4
90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017912042
91 https://doi.org/10.1007/978-3-319-22539-5_12
92 schema:sdDatePublished 2022-12-01T06:49
93 schema:sdLicense https://scigraph.springernature.com/explorer/license/
94 schema:sdPublisher N8ffcc4c0f97849adb8eccac44699ac2b
95 schema:url https://doi.org/10.1007/978-3-319-22539-5_12
96 sgo:license sg:explorer/license/
97 sgo:sdDataset chapters
98 rdf:type schema:Chapter
99 N018c392b2448417ca7a959e8c9f6cc1e schema:name doi
100 schema:value 10.1007/978-3-319-22539-5_12
101 rdf:type schema:PropertyValue
102 N04e1af42f25c4970b5e0f475adebdd53 rdf:first N75ee960e295d442db93211b5a350eae8
103 rdf:rest Nca80f9ecfea94491bd4997d677569e5f
104 N0e00557dead545168e72654602757f15 schema:isbn 978-3-319-22538-8
105 978-3-319-22539-5
106 schema:name Melanoma
107 rdf:type schema:Book
108 N23402d1de43145b08f147e818c4bb08d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Immunotherapy
110 rdf:type schema:DefinedTerm
111 N2775bbe5963f47f98bcfeb953ddcecc5 schema:familyName Mehnert
112 schema:givenName Janice M.
113 rdf:type schema:Person
114 N3edeb008b3724f63955ca1dcc32c7e2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Neoplasm Staging
116 rdf:type schema:DefinedTerm
117 N51374dfae47143259674d31d0d165a90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Prognosis
119 rdf:type schema:DefinedTerm
120 N58cf14a13d1f426798a2b1a593c4b888 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Humans
122 rdf:type schema:DefinedTerm
123 N75ee960e295d442db93211b5a350eae8 schema:familyName Kaufman
124 schema:givenName Howard L.
125 rdf:type schema:Person
126 N8bb6d07e409642aab7e48739077e36f1 schema:name dimensions_id
127 schema:value pub.1017912042
128 rdf:type schema:PropertyValue
129 N8fded5880d2048aca1afe621e6f52def schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Melanoma
131 rdf:type schema:DefinedTerm
132 N8ffcc4c0f97849adb8eccac44699ac2b schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 N9afe88cf538b4cf8b1f5fcd76c16279d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Protein Kinase Inhibitors
136 rdf:type schema:DefinedTerm
137 Nbdfd3ef30aa740c0a6cf9a580df50f27 rdf:first sg:person.01121172646.82
138 rdf:rest Ne3f8e96742684006b41bc85cc483311f
139 Nca80f9ecfea94491bd4997d677569e5f rdf:first N2775bbe5963f47f98bcfeb953ddcecc5
140 rdf:rest rdf:nil
141 Nd1bf24005c344baab87e348565143bb4 schema:name Springer Nature
142 rdf:type schema:Organisation
143 Ne3f8e96742684006b41bc85cc483311f rdf:first sg:person.0726366600.25
144 rdf:rest rdf:nil
145 Nf1cd30279932483aa8987ad19b5bd747 schema:name pubmed_id
146 schema:value 26601868
147 rdf:type schema:PropertyValue
148 Nf3ae2515de8142c98f0bcc4fe413b7a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Molecular Targeted Therapy
150 rdf:type schema:DefinedTerm
151 Nf42e6dcdb29942c2880ee2c7870206d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Uveal Neoplasms
153 rdf:type schema:DefinedTerm
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
158 schema:name Oncology and Carcinogenesis
159 rdf:type schema:DefinedTerm
160 sg:person.01121172646.82 schema:affiliation grid-institutes:grid.51462.34
161 schema:familyName Shoushtari
162 schema:givenName Alexander N.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121172646.82
164 rdf:type schema:Person
165 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
166 schema:familyName Carvajal
167 schema:givenName Richard D.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
169 rdf:type schema:Person
170 grid-institutes:grid.239585.0 schema:alternateName Melanoma and Experimental Therapeutics Services, Columbia University Medical Center, 161 Fort Washington Avenue, 10032, New York, NY, USA
171 schema:name Melanoma and Experimental Therapeutics Services, Columbia University Medical Center, 161 Fort Washington Avenue, 10032, New York, NY, USA
172 rdf:type schema:Organization
173 grid-institutes:grid.51462.34 schema:alternateName Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA
174 schema:name Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA
175 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...